A first in class Plasmacytoid Dendritic cell line, PDC*line providing unmatched advantages

  • Potent & effective

    Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

  • Scalable & convenient

    Simple production of a large quantity of a highly qualified off-the-shelf product

  • Versatile & applicable to any cancers

    The peptides can easily be changed to target a specific cancer type

News

Three Belgian investment funds and several specialized international business angels have participated in this round, which will allow the company’s cancer immunotherapy technology to reach the clinical proof of concept phase. Liège, Belgium,Read more

Candidate products

product-pdc-mel

Melanoma,
Advanced stage

pdcline_melanome_home

Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

READ MORE

product-pdc-lung

Lung Cancer,  Non-Small Cell,
Advanced stage

pdc-lung-thumb

1.8 million new cases of lung cancer were diagnosed worldwide in 2012, and this disease was responsible for and 1.6 million deaths. Lung cancer is therefore the most frequently diagnosed cancer and the leading cause of cancer mortality.

About 40% of patients are diagnosed with locally advanced (stage IIIb) or metastatic (stage IV) cancer; prognosis is poor (median survival 8-13 months).

READ MORE

PDC*line Pharma

thumbnail-pdcvactechnology

Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a clinical-stage biotech company that develops a new class of antigen – specific active immunotherapies based on a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line).

PDC*mel, our leading drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer.

about us

icone-logo SUBSCRIBE TO THE PDC*LINE NEWS